scholarly journals A Promising Effect of Pravastatin For Reducing Preeclamsia Incidence In High Risk Pregnant Women

2019 ◽  
Vol 1 (1) ◽  
pp. 1-8
Author(s):  
Fariska Zata ◽  
Mohammad Nasir
Keyword(s):  
Cardiovascular Disease ◽  
High Risk ◽  
Pregnant Women ◽  
Low Dose ◽  
Early Prevention ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Definitive Therapy ◽  
History Of

Preeclamsia is still a threat in obstetrics because it is the leading cause of maternal death (15-20% in developing countries). Globally, preeclampsia causes 70,000-80,000 pregnant women to die and 500,000 babies die annually1, with increased morbidity such as prematurity and fetal growth disturbance2. The exact cause of preeclampsia is still not clearly known (also called "The disease of theory"), but recent studies shows that the imbalance of pro-angiogenic (VEGF, PlGF) and anti-angiogenic factors (sFlt-1, s-Eng) plays an important role in the pathogenesis preeclampsia. The presence of general maternal endothelial dysfunction induced by an imbalance of these factors is a major phenomenon in preeclampsia, which results in placental hypoxia / ischemia, resulting in vasoconstriction resulting in hypertension1. Termination of pregnancy is still as a definitive therapy for preeclamsia. Therefore, early prevention is necessary in the management of preeclampsia. In 2013, ACOG recommended the administration of low-dose aspirin and calcium 1 gram / day to patients in pregnant women with high risk of preeclamsia3. However, low-dose aspirin is less useful in preventing preeclampsia in patients with a history of previous chronic hypertension4 and not reduce the incidence of term preeclampsia (the incidence of preeclampsia at gestational age above 37 weeks)5,6. This weakness of low-dose aspirin has led to recent research focusing on the prevention of preeclampsia. The similarity between the pathogenesis mechanism of preeclampsia and cardiovascular disease makes pravastatin (a protective therapy in cardiovascular disease before) as a potential agent for preventing preeclampsia7. Therefore, the role of pravastatin for reducing preeclampsia incidence in high risk pregnant women will be discussed in this article.

scholarly journals 48: Effect of obesity on platelet inhibition in high-risk pregnant women treated with low dose aspirin

2019 ◽  
Vol 220 (1) ◽  
pp. S38-S39 ◽  
Author(s):  
Matthew M. Finneran ◽  
Veronica M. Gonzalez-Brown ◽  
Devin D. Smith ◽  
Mark B. Landon ◽  
Kara Rood
Keyword(s):  
High Risk ◽  
Pregnant Women ◽  
Low Dose ◽  
Platelet Inhibition ◽  
Dose Aspirin ◽  
Low Dose Aspirin

scholarly journals 175: Effect of body size on preeclampsia risk-reducing potential of low-dose aspirin among high-risk pregnant women

2020 ◽  
Vol 222 (1) ◽  
pp. S124-S125
Author(s):  
James Lasky ◽  
Roxane Handal-Orefice ◽  
Desmond Sutton ◽  
Sheila Nemeth ◽  
Alexander M. Friedman ◽  
...  
Keyword(s):  
Body Size ◽  
High Risk ◽  
Pregnant Women ◽  
Low Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Risk Reducing ◽  
Reducing Potential

Role of Asprin in Healthy Elderly

JMS SKIMS ◽  
2018 ◽  
Vol 21 (1) ◽  
pp. 68-69
Author(s):  
Ajaz A Malik
Keyword(s):  
Cardiovascular Disease ◽  
Older Persons ◽  
Low Dose ◽  
Healthy Elderly ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Prevention Trials ◽  
Clinically Significant ◽  
Fatal Myocardial Infarction

Cardiovascular disease are among the principal causes of disability and death in older persons and therefore preventive interventions for such diseases are a high priority.Secondary prevention trials have established the efficacy of low dose aspirin for the prevention of cardiovascular disease (fatal , non-fatal myocardial infarction fatal or non-fatal stroke , or hospitalisation for heart failure). The benefits of low dose ASPRIN outweigh the risk of majorhaemorrhage (hemorrhagic stroke, symptomatic intracranial bleeding are clinically significant extra-cranial bleeding) associated with it in the secondary prevention of cardiovascular events. However, the role of low dose aspirin in primary prevention in elderly healthy individuals is unclear. JMS 2018;21(1):68-69

scholarly journals Effect of low dose aspirin on fetal outcome in women at risk for developing pregnancy induced hypertension

2020 ◽  
Vol 7 (4) ◽  
pp. 865
Author(s):  
Madhusmita Pradhan ◽  
Jyotiranjan Champatiray ◽  
Kishore V. S.
Keyword(s):  
Birth Weight ◽  
High Risk ◽  
Low Birth Weight ◽  
Pregnant Women ◽  
Gestational Age ◽  
Low Dose ◽  
Pregnancy Induced Hypertension ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Induced Hypertension

Background: Though pregnancy induced hypertension is a worldwide problem, it is more prevalent in developing countries particularly south east Asian and African countries. It contributes to 20% of perinatal death and 40-50% of low birth weight babies in India. Fetal salvage is also an important consideration in providing quality care. Low dose aspirin given between 12 weeks to 28 weeks of gestational age in high-risk women at Developing Pregnancy Induced Hypertension (PIH) is anticipated to prevent the development of PIH and complications that arises especially those regarding maternal and fetal mortality due to PIH.Methods: This prospective randomized controlled trial was conducted in the dept of O and G, SCB MC and Hospital, Cuttack during November 2018 to October 2019. Pregnant women between the gestational age of 13 to 28 week were screened for risk factors and included in this study. Low dose aspirin of 60 mg daily till delivery was given to pregnant women who consented to be a part of study randomly with the other group taking placebo.Results: Incidence of IUGR babies in low dose aspirin treated mothers was as low as 1%. Incidence of LBW babies is lower in low dose aspirin treated mothers than with those who were not treated. Mean birth weight in cases was 2780 gm±352 gm vs control 2592 gm±483 gm. There is increased incidence of still birth in high risk group not treated with aspirin. No significant difference in reducing incidence premature deliveries between case and control.Conclusions: Low dose aspirin has a definite role in the prevention of PIH in high risk pregnancy and its complication like IUGR and low birth weight. Low dose aspirin reduces the incidence of PIH. Low dose aspirin can be considered a safe drug without any deleterious side effect for mother and the fetus. Benefits of prevention of PIH, justifies its administration in women at high risk.

scholarly journals Effect of low dose aspirin on maternal outcome in women at risk for developing pregnancy induced hypertension

2020 ◽  
Vol 9 (4) ◽  
pp. 1590
Author(s):  
Madhusmita Pradhan ◽  
Kishore S. V. ◽  
Jyotiranjan Champatiray
Keyword(s):  
Risk Factors ◽  
High Risk ◽  
Pregnant Women ◽  
Low Dose ◽  
Multiple Pregnancy ◽  
Control Group ◽  
Pregnancy Induced Hypertension ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Induced Hypertension

Background: Pre-eclampsia is not totally a preventable disease. It is found more related to chains of social ills such as poor maternal nutrition, limited or no antenatal care and poor reproductive education. However, some specific “high-risk” factors leading to pregnancy induced hypertension (PIH) may be identified in individuals which include and not limited to young and elderly primigravida, multiple pregnancy, diabetes, Rh incompatibility, new paternity, pre-existing vascular or renal disease, family history of hypertension, pre-eclampsia and eclampsia, obesity, thrombophilia. Low dose aspirin given in 2nd trimester in these high-risk women is anticipated to prevent the development of PIH.Methods: This prospective randomized controlled trial was conducted in the department of obstetrics and gynecology, SCB MC and Hospital, Cuttack during November 2018 to October 2019. Pregnant women between the gestational age of 13th to 28th weeks were screened for risk factors and included in this study. Low dose aspirin of 60 mg daily till delivery was given to pregnant women who consented to be a part of study randomly with the other group having placebo.Results: Protienuric hypertension was high in control group who did not receive aspirin. Low dose aspirin significantly reduces PIH in high-risk group (3.48% in case versus 23.52% in control). Low dose aspirin was not associated with significant increase in placental bleeding. Low dose aspirin was generally safe for the fetus and new born infant with no evidence of an increased likelihood of bleeding.Conclusions: Low dose aspirin has a definite role in the prevention of PIH in high risk pregnancy. Low dose aspirin reduces the incidence of PIH. Low dose aspirin can be considered a safe drug without any deleterious side effect for mother and the fetus. Benefits of prevention of PIH, justifies its administration in women at high risk.

scholarly journals AB0295 TREATMENT OF HIGH RISK/REFRACTORY OBSTETRIC ANTIPHOSPHOLIPID SYNDROME. A SINGLE CENTRE EXPERIENCE

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1174.1-1174
Author(s):  
A. Hoxha ◽  
P. Marson ◽  
M. Favaro ◽  
M. Tonello ◽  
M. Zen ◽  
...  
Keyword(s):  
High Risk ◽  
Antiphospholipid Syndrome ◽  
Pregnancy Complications ◽  
Low Dose ◽  
Treatment Protocol ◽  
Line Treatment ◽  
Second Line ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
History Of

Background:The most efficacious strategy to manage pregnant patients with antiphospholipid syndrome (APS) who are at high risk of adverse pregnancy outcomes ± refractory to conventional heparin/low-dose aspirin treatment is currently unknown (1, 2).Objectives:The purposes of this study were to investigate the efficacy and safety of a second-line treatment protocol administered in addition to twice daily low molecular weight heparin and low-dose aspirin to pregnant patients affected with high-risk ± refractory primary APS.Methods:Patients were included in the study if satisfying the following criteria were: 1) the presence of triple antiphospholipid antibody positivity (IgG/IgM anticardiolipin + IgG/IgM anti-β2 Glycoprotein I antibodies + lupus anticoagulant), 2) previous thrombosis and/or a history of one or more early and severe pregnancy complications. The second-line treatment protocol included weekly plasmapheresis or immunoadsorption and fortnightly 1g/kg intravenous immunoglobulins.Results:Twenty-four pregnancies occurring between 2002 and 2019 in 19 primary APS patients, (mean age 35.1 ± 3.5 SD) were monitored. Triple antiphospholipid positivity was detected in all 19 cases (100%). Seven of these women (36.8%) had a history of thrombosis, five (26.3%) one or more previous failed pregnancies associated to severe pregnancy complications and seven (36.8%) both clinical criteria. Twenty- three pregnancies (95.8%) produced live neonates (13 females and 10 males), all born between the 26th and 38th week of gestation (mean 33.6 ± 3.5 SD); birth weight percentile was 35.8 ± 24.1 SD and mean Apgar score at 5 min 8.7 ± 1.1 SD. Due to premature birth (24th week) complicated by fetal sepsis, one pregnancy (4.2%) had a negative outcome. During the treated pregnancy there were no episodes of thrombosis; there were five cases (20.8%) of severe maternal complications during pregnancy or puerperium and four of fetal complications (16.6%), all followed by complete recovery after delivery. No side-effects of the treatment were registered.Conclusion:Given the high live birth rate and the safety associated to it, the second-line treatment protocol described here could be taken into consideration when the treatment of a high-risk APS pregnancy ± refractory to conventional therapy is being evaluated.References:[1]Tektonidou MG, et al. Ann Rheum Dis 2019;0:1–9. doi:10.1136/annrheumdis-2019-215213[2]Giacomelli et al. Autoimmun Rev. 2020;102738. doi.org/10.1016/j.autrev.2020.102738Disclosure of Interests:None declared

Impact of educational preeclampsia prevention booklet on knowledge and adherence to low dose aspirin among pregnant women with high risk for preeclampsia

2020 ◽  
Vol 30 (6) ◽  
Author(s):  
Rella Indah Karunia ◽  
Anita Purnamayanti ◽  
Fransiscus O.H. Prasetyadi
Keyword(s):  
High Risk ◽  
Pregnant Women ◽  
Low Dose ◽  
P Value ◽  
Dose Aspirin ◽  
Validated Questionnaire ◽  
Low Dose Aspirin ◽  
Significant Difference ◽  
Before And After ◽  
The Impact

AbstractBackgroundPostpartum bleeding and pregnancy induced hypertension – including preeclampsia – remain to be a great cause of maternal mortality. The use of aspirin for preventing preeclampsia has been practiced recently by fetomaternal specialists in Indonesia. This study aimed to analyze the impact of education using an aspirin booklet provided by pharmacists on knowledge and adherence in taking aspirin among pregnant women with high risk for preeclampsia.MethodsThis was one group of pretest-posttest study. We enrolled all pregnant women with high risk for preeclampsia screened at 11+0–13+6 weeks’ gestation at Fetomaternal Clinic, Dr. Ramelan Naval Hospital, Surabaya. All subjects prescribed with low-dose aspirin (100 mg) for preeclampsia prevention received oral and written education using the aspirin booklet and had been followed up for 2 months. Knowledge about aspirin for preeclampsia prevention was measured by a validated questionnaire developed for this study. Adherence to aspirin was measured by pill count method.ResultsA total of 12 pregnant women with high risk for preeclampsia were included during the study period. This study showed a statistically significant difference on knowledge of preeclampsia prevention before and after receiving oral and written education using aspirin booklet (p-value = 0.020), as well as aspirin adherence (p-value = 0.011).ConclusionThe use of oral education and written aspirin booklet provided by pharmacists had impact on knowledge of preeclampsia prevention and adherence in taking aspirin among pregnant women with high risk for preeclampsia. We recommend to conduct randomized control study of adequate number of subjects.

Sign in / Sign up

Export Citation Format

Share Document